logo

For the Inventor, By the Inventor

Rahway, NJ, United States of America

Francis J Dumont

This inventor holds 8 USPTO granted patents. Top assignee: Merck + Co., Inc.. Active years: 1990-1994.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Francis J Dumont. Retrieved from https://idiyas.com/inventor/francis-j-dumont

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8

% Patents Active = 100.0

Average Co-Inventor Count = 4.6

ph-index = 5

Forward Citations = 82(Granted Patents)


Company Filing History:

goldMedal8 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1990-1994

Loading Chart...
8 patents (USPTO):Explore Patents
1. 5342935 - Antagonists of immunosuppressive macrolides (1994-08-30),
2. 5273979 - C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent (1993-12-28),
3. 5225403 - C-21 hydroxylated FK-506 antagonist (1993-07-06),
4. 5194378 - Process for producing FK-506 (1993-03-16),
5. 5190950 - Antagonists of immunosuppressive macrolides (1993-03-02),
6. 5149701 - C-31 methylated FR-900520 cyclic hemiketal immunosuppressant agents (1992-09-22),
7. 5116756 - Process for producing FK-506 (1992-05-26),
8. 4914188 - Novel 6-position cyclosporin analogs as non-immunosuppressive (1990-04-03),

Title: Innovations of Francis J Dumont

Introduction

Francis J Dumont is a notable inventor based in Rahway, NJ (US). He has made significant contributions to the field of immunosuppressants, holding a total of 8 patents. His work has been instrumental in advancing medical treatments for autoimmune diseases and organ transplants.

Latest Patents

Dumont's latest patents include innovative compounds that serve as antagonists of FK-506-type immunosuppressants. One of his key inventions involves hydroxymacrolides and derivatives that are prepared from suitable precursors through oxidation at C-20. These macrolides are particularly useful for modifying dosages of FK-506-type immunosuppressants in treating autoimmune diseases, infectious diseases, and preventing rejection of foreign organ transplants. Additionally, these compounds can act as antidotes for overdoses of FK-506-type immunosuppressants. Another significant patent describes a process for producing a new immunosuppressant, a C-31 desmethyl, C-19/C-22 cyclic hemiketal biotransformation analog of FR-900520. This process utilizes the novel microorganism, Streptomyces lavendulae ATCC No. 55209, under unique fermentation conditions. The C-31 methylated derivative produced by enzymatic methylation further enhances the utility of these macrolide immunosuppressants in preventing human host rejection of foreign organ transplants.

Career Highlights

Dumont is currently associated with Merck & Company, Inc., where he continues to innovate in the field of pharmaceuticals. His work has not only contributed to the scientific community but has also had a profound impact on patient care and treatment options.

Collaborations

Some of his notable coworkers include Byron H Arison and Thomas R Beattie, who have collaborated with him on various projects, enhancing the scope and impact of their research.

Conclusion

Francis J Dumont's contributions to the field of immunosuppressants exemplify the importance of innovation in medicine. His patents and ongoing work continue to pave the way for advancements in treatment options for patients worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…